Latest Headlines

Latest Headlines

Sanofi recalls pediatric H1N1 shots

Sanofi-Aventis is recalling some 800,000 pediatric doses of H1N1 vaccine because tests showed some batches weren't potent enough, the Centers for Disease Control and Prevention said. The CDC said the

Measles death rate dips, but experts fear resurgence

Measles deaths declined 78 percent between 2000 and 2008 due to a global initiative to promote childhood vaccination. However, immunization experts warn of a resurgence in deaths if vaccination

Vax competition pushes down prices for poor

The GAVI Alliance--a Geneva-based public-private partnership aimed at improving health in the world's poorest countries--touted the news this week that millions of more children would be able to

Pfizer spreads vaccine R&D in post-merger shakeup

The R&D upheaval now underway at the newly merged operations of Pfizer and Wyeth will leave a number of research facilities involved in vaccine work. Wyeth's complex in Collegeville, PA--which

Kineta, UW scientists reap $13M adjuvant grant

Tiny Seattle-based Kineta has reaped $6.8 million of a $13 million grant to fund the development of new adjuvants for vaccines. And the rest of the money will go to Michael Gale Jr. and Michael

Doubling up on flu shots OK, study shows

Simultaneous vaccination against seasonal and pandemic flu provides protection against the virus without provoking significant side effects, according to a clinical study released by GlaxoSmithKline.

Dutch pull Pfizer infant vaccine after deaths

Dutch health authorities have yanked a batch of Pfizer's Prevnar following the deaths of three infants. Prevnar, which is known as Prevenar in Europe, is used to protect infants from certain

HPV vax successfully treats precancerous lesions

Millions of women who carry the human papillomavirus suffer from precancerous lesions. But a small study indicates that an HPV vaccine may either improve their condition or cure it altogether,

Novartis wants China as its No. 3 market

Novartis has upped the ante in China. Today, the Swiss drugmaker said it was buying an 85 percent chunk of the Chinese vaccines maker Zhejiang Tianyuan for $125 million. And that's just one-tenth of

Global vax market growing at 16% clip

We all know vaccines have emerged as a major growth engine for pharma. No longer an also-ran business, vaccines are becoming big-time business stars, backed by major DTC campaigns--think Garadasil's